Clinical trial

CKM For Safe Use of SGLT2i in Type 1 Diabetes

NCT07211802

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-07-01

PhasePHASE3

Study timeline

Study start (estimated)2026-07-01Date precision: day

Registry last updated2025-10-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 1 Diabetes (T1D)unresolved

Interventions

Sotagliflozin Low DoseDRUG

Sotagliflozin High DoseDRUG

Dual Continuous Glucose and Ketone MonitorDEVICE

Sponsors & collaborators

University of California, San Diegolead sponsor

National Institutes of Health (NIH)collaborator

Abbottcollaborator

Lexicon Pharmaceuticalscollaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)collaborator

Mapped research locations

La JollaCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07211802 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.